Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

[Platelet inhibitors in clinical practice].

Gebhard C, Beer J.

Ther Umsch. 2012 Nov;69(11):617-29. doi: 10.1024/0040-5930/a000339. Review. German.

PMID:
23117664
2.

New antiplatelet agents in the treatment of acute coronary syndromes.

Sabouret P, Taiel-Sartral M.

Arch Cardiovasc Dis. 2014 Mar;107(3):178-87. doi: 10.1016/j.acvd.2014.01.009. Epub 2014 Mar 11. Review.

3.

Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?

Varenhorst C, James S.

Curr Cardiol Rep. 2012 Aug;14(4):486-92. doi: 10.1007/s11886-012-0273-y. Review.

PMID:
22535473
4.

Acute coronary syndromes: identifying the appropriate patient for prasugrel.

Stephens JC, Askari AT.

Postgrad Med. 2012 Mar;124(2):16-28. doi: 10.3810/pgm.2012.03.2533. Review.

PMID:
22437212
5.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.

6.

Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?

Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J.

Med Sci Monit. 2009 Dec;15(12):MS24-30. Review.

PMID:
19946242
7.

Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?

Alber HF, Huber K, Pachinger O, Frick M.

Wien Klin Wochenschr. 2011 Aug;123(15-16):468-76. doi: 10.1007/s00508-011-0027-7. Epub 2011 Aug 3. Review.

PMID:
21800048
8.

Development and clinical use of prasugrel and ticagrelor.

Ahmad S, Storey RF.

Curr Pharm Des. 2012;18(33):5240-60. Review.

PMID:
22724412
9.

Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.

Packard KA, Campbell JA, Knezevich JT, Davis EM.

Pharmacotherapy. 2012 Mar;32(3):244-73. doi: 10.1002/j.1875-9114.2012.01021.x. Review.

PMID:
22392457
10.

ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.

Oprea AD, Popescu WM.

J Cardiothorac Vasc Anesth. 2013 Aug;27(4):779-95. doi: 10.1053/j.jvca.2012.11.014. Epub 2013 May 3. Review. No abstract available.

PMID:
23648080
11.

New anti-platelet agents: the end of resistance?

Kastrati A.

Thromb Res. 2012 Oct;130 Suppl 1:S53-5. doi: 10.1016/j.thromres.2012.08.275. Review.

PMID:
23026663
12.

TRITON and beyond: new insights into the profile of prasugrel.

Jakubowski JA, Riesmeyer JS, Close SL, Leishman AG, Erlinge D.

Cardiovasc Ther. 2012 Aug;30(4):e174-82. doi: 10.1111/j.1755-5922.2011.00263.x. Epub 2011 Feb 17. Review.

13.

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

Wang WE, Wang H, Wang X, Zeng C.

J Thromb Thrombolysis. 2014;37(2):102-6. doi: 10.1007/s11239-013-0918-8. Review.

PMID:
23584598
14.

Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.

Wijeyeratne YD, Joshi R, Heptinstall S.

Expert Rev Clin Pharmacol. 2012 May;5(3):257-69. doi: 10.1586/ecp.12.17. Review.

PMID:
22697589
15.
16.

Antiplatelet options for secondary prevention in acute coronary syndromes.

Silvain J, Cayla G, O'Connor SA, Collet JP, Montalescot G.

Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1403-15. doi: 10.1586/erc.11.139. Review.

PMID:
22059790
17.

Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.

Piccolo R, Di Gioia G, Niglio T, D'Anna C, De Rosa R, Strisciuglio T, Bevilacqua M, Piscione F, Cirillo P, Galasso G.

Angiology. 2014 Feb;65(2):130-6. doi: 10.1177/0003319712467530. Epub 2012 Dec 4. Review.

PMID:
23221279
18.

Thienopyridine antiplatelet agents: focus on prasugrel.

Freeman MK.

Consult Pharm. 2010 Apr;25(4):241-57. doi: 10.4140/TCP.n.2010.241. Review.

PMID:
20511177
19.

Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.

Lyseng-Williamson KA.

Am J Cardiovasc Drugs. 2012 Jun 1;12(3):207-16. doi: 10.2165/11209640-000000000-00000.

PMID:
22583148
20.

[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].

Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C.

Dtsch Med Wochenschr. 2011 Apr;136(15):782-5. doi: 10.1055/s-0031-1272567. Epub 2011 Mar 22. Review. German. No abstract available.

PMID:
21432747

Supplemental Content

Support Center